Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

First Results of Concurrent Chemoradiation with Two Courses of 5 × 25 mg/m<sup>2</sup> Cisplatin for Locally Advanced Head and Neck Cancer.

Journal of personalized medicine·2023
Same author

Hypo-fractionated Radiotherapy (HF-RT) <i>Versus</i> Conventionally Fractionated Radiotherapy (CF-RT) for Glioblastoma.

Anticancer research·2023
Same author

Whole-brain Radiotherapy With or Without a Simultaneous Integrated Boost for Treatment of Brain Metastases.

Anticancer research·2023
Same author

Radiosurgery for ventricular tachycardia (RAVENTA): interim analysis of a multicenter multiplatform feasibility trial.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2023
Same author

Prognostic impact of the loss of E-cadherin and <i>de novo</i> expression of N-cadherin at the invasive front of primary and recurrent oral squamous cell carcinoma.

Frontiers in oncology·2023
Same author

Differential Effects of Anti-PD-1/PD-L1 Checkpoint Inhibitors on Adhesion Molecules and Cytokine Secretion by THP-1 Monocytes.

Anticancer research·2023

相关实验视频

Updated: Jul 15, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

同时的对抗. 顺序提升辅助乳腺放射治疗的顺序提升

Marie C Eggert1, Stefan Janssen1, Nathan Y Yu2

  • 1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.

Anticancer research
|September 29, 2023
PubMed
概括

与顺序增强剂 (CF+SEB) 相比,用于乳腺癌的同步综合增强剂 (CF+SIB) 的常规分化显示了与顺序增强剂 (CF+SEB) 相似的长期结果和毒性,但将治疗时间缩短了一周.

关键词:
乳腺癌 乳腺癌 乳腺癌辅助性辐射辐射是什么顺序性提升的提升是顺序性的.同时的集成提升.有毒性 有毒性 有毒性治疗的结果.

更多相关视频

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.2K

相关实验视频

Last Updated: Jul 15, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K
Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.2K

科学领域:

  • 在瘤学瘤学.
  • 辐射瘤学 辐射瘤学
  • 临床试验 临床试验

背景情况:

  • 乳腺癌的辅助放射治疗 (RT) 已经看到替代疗法的增加.
  • 同时集成增压 (SIB) 越来越受欢迎,而不是连续增压 (SEB).

研究的目的:

  • 在乳腺癌患者中,比较常规分离 (CF) 加SIB与CF加SEB的长期结果.
  • 评估两种辅助放射治疗方法之间的毒性概况和生存率.

主要方法:

  • 一个匹配的队列研究,将48名接受CF+SIB (5.5周) 的患者与72名接受CF+SEB (6.5周) 的患者进行比较.
  • 患者根据十二个特征进行了匹配.
  • 评估的结果包括辐射皮肤炎,肺炎,局部控制 (LC),无转移生存率 (MFS),癌症特异性生存率 (CSS) 和整体生存率 (OS).

主要成果:

  • 2级以上皮肤炎的发生率为35.4% (CF+SIB) 和45.8% (CF+SEB) (p=0.26).
  • 2级以上肺炎的发生率为0% (CF+SIB) 和4.2% (CF+SEB) (p=0.27).
  • 在CF+SIB和CF+SEB组中,六年生存率 (LC,MFS,CSS,OS) 在CF+SIB和CF+SEB组之间是可比的,没有统计学上显著的差异.

结论:

  • 常规分化与同时集成增强剂 (CF+SIB) 是用于辅助乳腺癌放射治疗的顺序增强剂 (CF+SEB) 的可行替代方案.
  • CF+SIB的疗效和毒性与CF+SEB的疗效和毒性相当.
  • CF+SIB显著减少了整体治疗持续时间一周.